Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | STS | P08842 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACR | P10323 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13266961 | 0.94 | CA1 (0.58) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL15382504 | 0.90 | ACACB (0.56) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL3017371 | 0.87 | MAPT (0.50) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL934140 | 0.85 | CA1 (0.60) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL28303307 | 0.85 | CA1 (0.60) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL28050325 | 0.85 | CA1 (0.60) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL514352 | 0.84 | CA1 (0.64) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL28584064 | 0.83 | CA1 (0.58) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL28265102 | 0.83 | PPARA (0.61) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL2826124 | 0.83 | CA1 (0.53) | CA1CA2MAPTTDP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232616-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. | 2015-08-20 | — | — | US | disclosed |
| US-8980326-B2 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8779008-B2 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140170225-A1 | IMMUNOTHERAPY FOR TREATMENT OF AMYLOID-RELATED DISORDERS USING ENCAPSULATED BETA-AMYLOID PEPTIDES | INTEZYNE TECHNOLOGIES INC (US) | 2014-06-19 | — | — | US | disclosed |
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8426477-B1 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8299128-B2 | Compositions comprising polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8268936-B2 | Synthesis of hybrid block copolymers and uses thereof | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8263665-B2 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263663-B2 | Azide functionalized peptide targeting groups | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-4699698-A | Preparation of benzoic acid ortho-esters and novel compounds of this type | BASF AKTIENGESELLSCHAFT (DE) | 1987-10-13 | — | — | US | disclosed |
| US-4612092-A | TRIARYLAMINE, ELECTROLYSIS | BASF AKTIENGESELLSCHAFT (DE) | 1986-09-16 | — | — | US | disclosed |
| US-RE30812-E | ANTIARRHTHMIA AGENTS | MEAD JOHNSON & COMPANY (US) | 1981-12-01 | — | — | US | disclosed |
| US-RE30811-E | SEROTONIN ANTAGONISTS, ANTIARRHYTHMIA AGENTS | MEAD JOHNSON & COMPANY (US) | 1981-12-01 | — | — | US | disclosed |
| US-4064254-A | ANTIARRHYTHMIC AND ANTISEROTONINE AGENTS | MEAD JOHNSON & COMPANY (US) | 1977-12-20 | — | — | US | disclosed |
| US-4000143-A | ANTIARRHYTHMIC AND ANTISEROTONIN AGENTS | MEAD JOHNSON & COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
| US-3931195-A | ANTIARRHYTHMIA, ANTISEROTONIN | MEAD JOHNSON & COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, CLTB, CD47 | CA1 1445/4885CA2 2651/4885MAPT 102/4885 |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | CA1 2297/4885CA2 1511/4885MAPT 3612/4885 |
| US-20140170225-A1 | IMMUNOTHERAPY FOR TREATMENT OF AMYLOID-RELATED DISORDERS USING ENCAPSULATED BETA-AMYLOID PEPTIDES | IAPP, APP, TTR | CA1 1551/4885CA2 3748/4885MAPT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.